Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01431339 is registered in ClinicalTrials.gov with Durata Therapeutics Inc., an affiliate of Allergan plc as lead sponsor.

NCT NCT01431339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01431339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2011
Completion date
December 31, 2012
Enrollment
739 (actual)
Sites
137

Conditions

As the registry lists them; a condition with its own page is linked.

abscess, cellulitis, surgical site infection, wound infection